홈MCP워크벤치Skills
홈워크벤치알림마이페이지
Huagongshe 오픈 프로젝트:[email protected]AI 접속: llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.7.8
  1. 홈
  2. /화합물

메스티논

Pyridostigmine Bromide

HCID 7550
노트반응
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
101-26-8
표준 SMILES
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]
InChIKey
VNYBTNPBYXSMOO-UHFFFAOYSA-M
분자식
C9H13BrN2O2
평균 분자량
261.12 g/mol
단동위원소 질량
260.01604

개요

Pyridostigmine bromide is a pyridinium salt.

이름 및 식별자

우선 이름
Pyridostigmine Bromide
IUPAC
(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate bromide
현지명
메스티논
영어명
Mestinon
분자식
C9H13BrN2O2
분자량
261.12

이름 및 동의어

PYRIDOSTIGMINE BROMIDE101-26-8KaliminKalyminRegonolRegonalMestinon bromidePyridostigmini bromidumPiridostigmina bromuroDTXSID9023540NSC-679759NSC-758435
이름 더 보기
메스티논PYBR3-(DIMETHYLCARBAMOYLOXY)-1-METHYLPYRIDINIUM BROMIDEro1-5130mestinon3-Hydroxy-1-mestinonbromide
Ro 1-5130KVI301NA533-Hydroxy-1-methylpyridinium bromide dimethylcarbamate3-(Dimethylcarbamyloxy)-1-methylpyridinium bromidePyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-, bromide1-Methyl-3-hydroxypyridinium bromide dimethylcarbamateRO-1-5130DTXCID503540

데이터베이스 식별자

CAS
101-26-8
PubChem CID
7550
DTXSID
DTXSID9023540
ChEMBL
CHEMBL812
ChEBI
CHEBI:8666
UNII
KVI301NA53
EC Number
202-929-9

물성

구조 계산 물성

극성 표면적
33.4 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
3
회전 가능 결합 수
2
무거운 원자 수
14
형식 전하
0
복잡도
182

실험 및 물리화학적 성질

OdorAGREEABLE ODOR
Color/FormWHITE OR PRACTICALLY WHITE, CRYSTALLINE POWDER
Solubility · 2건

FREELY SOL IN WATER, ALCOHOL, PRACTICALLY INSOL IN ETHER, ACETONE, BENZENE

FREELY SOL IN CHLOROFORM, SLIGHTLY SOL IN SOLVENT HEXANE

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Cholinesterase Inhibitors; Parasympathomimetics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point152-154 °C
Collision Cross Section137.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Other Experimental PropertiesHYGROSCOPIC

물리화학적 성질

녹는점
154 °C · 154 °C
저장 조건
2 · 2-8°C
용해도
물과 에탄올(96%)에 매우 잘 녹습니다.
물리적 상태
Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H300 (72.6%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P261, P262, P264, P270, P271, P272, P280, P284, P301+P316, P302+P352, P304+P340, P316, P320, P321, P330, P333+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 62 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 2 (72.6%)

독성 정보

Body Burden · 1건

Breast milk concn of pyridostigmine was determined in 2 nursing mothers who were receiving oral doses of pyridostigmine bromide, 120-300 mg daily. The amt of pyridostigmine per kg body wt ingested by the nursing infant was only 0.1% or less than that taken by the mother.

Treatment · 1건

If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.

Interactions · 5건

ACTIONS OF ANTICHOLINESTERASE AGENTS ON AUTONOMIC EFFECTOR CELLS & ON CORTICAL & SUBCORTICAL SITES IN CNS, WHERE RECEPTORS ARE LARGELY OF MUSCARINIC TYPE, ARE BLOCKED BY ATROPINE. /ANTI-CHE AGENTS/

화학 및 산업

약리 정보

Mechanism of Action · 3건

...PHARMACOLOGICAL EFFECTS OF ANTICHOLINESTERASE AGENTS ARE DUE PRIMARILY TO PREVENTION OF HYDROLYSIS OF /ACH/ ACETYLCHOLINE BY ACHE /ACETYLCHOLINESTERASE/ @ SITES OF CHOLINERGIC TRANSMISSION. TRANSMITTER THUS ACCUMULATES, AND THE ACTION OF ACH /ACETYLCHOLINE/ THAT IS LIBERATED BY CHOLINERGIC IMPULSES OR THAT LEAKS FROM THE NERVE ENDING IS ENHANCED.

Following admin of pyridostigmine bromide to rats, erythrocyte acetylcholinesterase activity recovered only slowly due to the covalent nature of inhibition. The logarithm of the plasma concn of pyridostigmine bromide was linearly related to the increase in tibialis twitch tension due to facilitation of neuromuscular transmission.

Of 12 analogs of pyridostigmine prepared by reacting 2-substituted 3-pyridinols with the desired carbamoyl chloride 2-iodo-3-(dimethylcarbamoyloxy)pyridine methiodide was the most active inhibitor of acetylcholinesterase and butyrylcholinesterase. The progressive inhibition curves for AChE and BuChE are compared and related to ionic attraction and steric requirements of the inhibitors.

Biological Half-Life · 1건

After admin of pyridostigmine bromide (200 nmol/kg, iv) to human subjects, the disposition half-life was 0.6-1.78 min and terminal half-life was 14.81-37.01 min. Clearance was 9.3-26.5 ml/min/kg which was greater than the presumptive value for glomerular filtration rate and the vol of distribution was 246.5-833.9 ml/kg.

Metabolism/Metabolites · 2건

PYRIDOSTIGMINE AND ITS QUATERNARY ALCOHOL ARE...THE PREDOMINANT ENTITIES FOUND IN URINE AFTER ADMIN OF THIS DRUG TO MAN.

Hydrolysis by cholinesterases and by liver. Half Life: 3 hours following oral administration.

FDA Pharmacological Classification · 4건

PYRIDOSTIGMINE BROMIDE

Cholinesterase Inhibitors [MoA]; Cholinesterase Inhibitor [EPC]

PYRIDOSTIGMINE BROMIDE ORAL

Cholinesterase Inhibitors [MoA]; Cholinesterase Inhibitor [EPC]

MeSH Pharmacological Classification · 1건

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

관련 반응

0건
반응 기록 만들기

현재 필터 조건에 해당하는 반응 기록이 없습니다.

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
색상
흰색에서 거의 흰색
Merck
14 · 14,7977
BCS Class
3 · 3
주요 응용
의약품(소분자)
InChI
InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
InChIKey
VNYBTNPBYXSMOO-UHFFFAOYSA-M
SMILES
C1(C=CC=[N+](C)C=1)OC(=O)N(C)C.[Br-]
EPA
3 · Pyridinium, 3-[[(dimethylamino)carbonyl]oxy]-1-methyl-, bromide (1:1) (101-26-8)

화학적 성질

White Solid

A SINGLE CASE HAS BEEN REPORTED IN WHICH METHOCARBAMOL MAY HAVE IMPAIRED THE THERAPEUTIC EFFECT OF PYRIDOSTIGMINE BROMIDE IN A PATIENT WITH MYASTHENIA GRAVIS.

In anesthetized patients, pyridostigmine bromide mestinon 10 mg iv antagonized the neuromuscular block induced by d-tubocurarine chloride 0.29 mg/kg/hr. Adequate recovery from the neuromuscular block should be judged by the return of the twitch height to the control level & also by the restoration of well-sustained tetanus 30 cycles/sec to the level seen before d-tubocurarine chloride administration.

Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure.

The amino acid gamma-aminobutyric acid (GABA), when given as supplement to pyridostigmine bromide reduced the incidence of malformations in chicken embryos.

Health Effects · 1건

Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.

Exposure RoutesPoorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.
Toxicity Summary · 1건

Pyridostigmine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.

Signs and Symptoms · 1건

Symptoms of low dose exposure include excessive salivation and eye-watering. Acute dose symptoms include severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Hypertension, hypoglycemia, anxiety, headache, tremor and ataxia may also result.

Human Toxicity Excerpts · 5건

EFFECTS...ON CENTRAL NERVOUS SYSTEM ARE...CHARACTERIZED BY STIMULATION OR FACILITATION AT VARIOUS SITES, SUCCEEDED BY INHIBITION OR PARALYSIS AT HIGHER CONCN. ... RESPIRATORY & OTHER SUBCORTICAL CENTERS LIKEWISE SHOW STIMULATION AFTER LOW DOSES AND DEPRESSION WITH HIGHER OR TOXIC DOSES. /ANTI-CHOLINESTERASE AGENTS/

GI SYMPTOMS OCCUR EARLIEST AFTER INGESTION, & INCL ANOREXIA, NAUSEA & VOMITING, ABDOMINAL CRAMPS, & DIARRHEA. WITH PERCUTANEOUS ABSORPTION OF LIQ, LOCALIZED SWEATING & MUSCULAR FASCICULATION IN IMMEDIATE VICINITY ARE GENERALLY EARLIEST MANIFESTATIONS. /ANTI-CHOLINESTERASE AGENTS/

...EFFECTS ON CNS INCL CONFUSION, ATAXIA, SLURRED SPEECH, LOSS OF REFLEXES, CHEYNE-STOKES RESP, GENERALIZED CONVULSIONS, COMA, & CENTRAL RESP PARALYSIS. ... TIME OF DEATH AFTER SINGLE ACUTE EXPOSURE MAY RANGE FROM LESS THAN 5 MIN TO NEARLY 24 HR, DEPENDING UPON DOSE, ROUTE, AGENT... CAUSE OF DEATH IS PRIMARILY RESPIRATORY FAILURE USUALLY ACCOMPANIED BY A SECONDARY CARDIOVASCULAR COMPONENT. /ANTI-CHOLINESTERASE AGENTS/

NICOTINIC ACTIONS @ NEUROMUSCULAR JUNCTIONS OF SKELETAL MUSCLE...FATIGABILITY & GENERALIZED WEAKNESS, INVOLUNTARY TWITCHINGS...SEVERE WEAKNESS & PARALYSIS; UNDOUBTABLY A CENTRAL COMPONENT OF ACTION CONTRIBUTES TO SOME OF THESE EFFECTS. THE MOST SERIOUS CONSEQUENCE...IS PARALYSIS OF RESPIRATORY MUSCLES. /ANTI-CHOLINESTERASE AGENTS/

For more Human Toxicity Excerpts (Complete) data for PYRIDOSTIGMINE BROMIDE (7 total), please visit the HSDB record page.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Pyridostigmine bromide

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Environmental Abiotic DegradationPhotolytic degradation of solutions of pyridostigmine bromide gave 3-hydroxy-l-methylpyridinium bromide and a small amt of unidentifiable tar.
Antidote and Emergency Treatment · 5건

1) ESTABLISH CLEAR AIRWAY & TISSUE OXYGENATION BY ASPIRATION OF SECRETIONS & IF NECESSARY, BY ASSISTED PULMONARY VENTILATION WITH OXYGEN. IMPROVE TISSUE OXYGENATION AS MUCH AS POSSIBLE BEFORE ADMINISTERING ATROPINE TO MINIMIZE THE RISK OF VENTRICULAR FIBRILLATION. /CARBAMATES, CHOLINESTERASE INHIBITORS/

2) ADMIN ATROPINE SULFATE IV, OR IM IF IV INJECTION IS NOT POSSIBLE... IN MODERATELY SEVERE POISONING: ADULT DOSAGE, INCLUDING CHILDREN OVER 12 YR: 0.4-2.0 MG REPEATED EVERY 15 MIN UNTIL ATROPINIZATION IS ACHIEVED (TACHYCARDIA, FLUSHING, DRY MOUTH, MYDRIASIS). MAINTAIN ATROPINIZATION BY REPEATED DOSES FOR 2-12 HR, OR LONGER, DEPENDING ON SEVERITY OF POISONING... DOSAGE FOR CHILDREN UNDER 12 YEARS: 0.05 MG/KG BODY WT REPEATED EVERY 15 MIN UNTIL ATROPINIZATION IS ACHIEVED. MAINTAIN ATROPINIZATION WITH REPEATED DOSAGE OF 0.02-0.05 MG/KG. SEVERELY POISONED INDIVIDUALS MAY EXHIBIT REMARKABLE TOLERANCE TO ATROPINE; TWICE THE DOSES SUGGESTED ABOVE MAY BE NEEDED... /CARBAMATES, CHOLINESTERASE INHIBITORS/

3. PRALIDOXIME (PROTOPAM-AYERST, 2-PAM) IS OF DOUBTFUL VALUE IN POISONINGS BY CARBAMATE INHIBITORS OF CHOLINESTERASE. ATROPINE ALONE IS ALMOST ALWAYS AN ADEQUATE ANTIDOTE. PRALIDOXIME IS PROBABLY CONTRAINDICATED IN POISONINGS BY CARBARYL, SPECIFICALLY. IF VICTIM OF CARBAMATE POISONING EXHIBITS SEVERE MUSCLE WEAKNESS &/OR RESPIRATORY DEPRESSION, OR IF POISONING INVOLVES A COMBINATION OF CARBAMATE & ORGANOPHOSPHATE, A DILUTE SOLUTION OF PRALIDOXIME (TOTAL DOSE IN 250 ML 5% GLUCOSE SOLN) MAY BE GIVEN CAUTIOUSLY IV. THE INFUSION SHOULD BE TERMINATED IF PATIENT'S CONDITION WORSENS. PRALIDOXIME DOSAGE: ADULTS, 1.0 G; FOR CHILDREN UNDER 12 YR, 20-50 MG/KG. 4. OBSERVE TREATED PATIENTS CLOSELY AT LEAST 24 HR TO INSURE THAT SYMPTOMS (POSSIBLY PULMONARY EDEMA) DO NOT RECUR AS ATROPINIZATION WEARS OFF. IN VERY SEVERE POISONINGS, METABOLIC DISPOSITION OF TOXICANT MAY REQUIRE SEVERAL HR OR DAYS DURING WHICH ATROPINIZATION MUST BE MAINTAINED. /CARBAMATES, CHOLINESTERASE INHIBITORS/

6. IF...INGESTED IN QUANTITY SUFFICIENT TO CAUSE POISONING, EMPTY THE STOMACH & INTESTINE. A. IF VICTIM IS ALERT & RESPIRATION IS NOT DEPRESSED, GIVE SYRUP OF IPECAC, FOLLOWED BY 1-2 GLASSES OF WATER TO INDUCE VOMITING; ADULTS (INCLUDING CHILDREN OVER 12), 30 ML; CHILDREN (UNDER 12 YR), 15 ML. CAUTION: OBSERVE VICTIM CLOSELY AFTER ADMIN IPECAC, IF CONSCIOUSNESS LEVEL DECLINES, OR IF VOMITING HAS NOT OCCURRED IN 15 MIN, PROCEED IMMEDIATELY TO INTUBATE THE STOMACH. FOLLOWING EMESIS, HAVE VICTIM DRINK A SUSPENSION OF /PRC: 30 G ACTIVATED CHARCOAL IN 3-4 OZ OF WATER (CHILDREN), 100 G IN 8-10 OZ OF WATER (ADULTS)/...TO BIND TOXICANT REMAINING IN THE GI TRACT. /CARBAMATES, CHOLINESTERASE INHIBITORS/

For more Antidote and Emergency Treatment (Complete) data for PYRIDOSTIGMINE BROMIDE (6 total), please visit the HSDB record page.

안전 데이터

wgk
3
rtecs
UU5270000
ridadr
UN 2811 6.1/PG 2
독성
man,TDLo,oral,9mg/kg (9mg/kg),PERIPHERAL NERVE AND SENSATION: FASCICULATIONS,Israel Journal of Medical Sciences. Vol. 27, Pg. 659, 1991.
HS 번호
2933399090
risk_code
26/27/28-43
hazard_code
T+
safety_code
22-36/37/39-45
포장분류
II
위험 등급
6.1
기존화학 물질
KE-11135
Hazard Classifications
Acute Tox. 1 InhalationAcute Tox. 2 DermalAcute Tox. 2 OralSkin Sens. 1
스토리지 클래스
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
유해 물질 데이터
101-26-8(Hazardous Substances Data)
Absorption, Distribution and Excretion · 2건

ITS ONSET OF ACTION BY ORAL ROUTE IS ABOUT 320 MIN...ITS DURATION OF ACTION BY THE ORAL ROUTE IS USUALLY SOMEWHAT LONGER AND ABSORPTION IS LESS ERRATIC THAN NEOSTIGMINE, WHICH ARE ADVANTAGES.

Plasma concn of pyridostigmine was determined in 2 nursing mothers who were receiving oral doses of pyridostigmine bromide, 120-300 mg daily. The drug was not detectable in infant plasma and there were no signs of drug effects in the infant.

용도 및 제조

Uses · 2건

MEDICATION

For the treatment of myasthenia gravis.

Methods of Manufacturing · 2건

URBAN, US PATENT NUMBER 2,572,579 (1951 TO HOFFMAN-LA ROCHE).

3-PYRIDINOL IS CONDENSED WITH DIMETHYLCARBAMOYL CHLORIDE IN THE PRESENCE OF A SUITABLE BASIC CATALYST SUCH AS DIMETHYLANILINE, MAGNESIUM OXIDE, ETC. THE RESULTING ESTER, 3-PYRIDYL DIMETHYLCARBAMATE, IS ISOLATED, DISSOLVED IN A SUITABLE ORGANIC SOLVENT, AND QUATERNIZED WITH METHYL BROMIDE.

Formulations/Preparations · 2건

AVAILABLE FOR ORAL USE IN 60-MG TABLETS, IN 180-MG SUSTAINED RELEASE TABLETS AND IN A SYRUP THAT CONTAINS 12 MG/ML, AS WELL AS IN AN INJECTABLE FORM THAT CONTAINS 5 MG/ML IN 2-ML AMPULS.

MESTINON IS AVAILABLE AS THE CHLORIDE SALT, UPON SPECIAL REQUEST FROM THE MANUFACTURER, ROCHE LABORATORIES.

응용 분야 · 3건

개요Pyridostigmine is an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE; IC50s = 0.35 and 1 μM, respectively, for the human enzymes). Pyridostigmine (10 μM) reduces decreases in AChE activity induced by the organophosphate pesticides diisopropyl fluorophosphate, chlorpyrifos-oxon, diazinon-oxon, paraoxon, and malaoxon in isolated bovine red blood cells. It also reduces soman-induced membrane depolarization and decreases in AChE activity in isolated human muscle bundles in a concentration-dependent manner. Pyridostigmine (3 mg/kg per day for four weeks) prevents tachycardia and increases in sympathetic tone in mice following myocardial infarction induced by left coronary artery ligation. Formulations containing pyridostigmine have been used in the treatment of myasthenia gravis and as neuromuscular protective agents against organophosphate poisoning.

용도Cholinergic, used in the treatment of myasthenia gravis, and is a pre-exposure antidote to chemical warfare agents.

일반 설명Pyridostigmine bromide,3-hydroxy-1-methylpyridinium bromide dimethylcarbamateor pyridostigmine bromide (Mestinon), occurs as a white, hygroscopic,crystalline powder with an agreeable, characteristicodor. It is freely soluble in water, alcohol, and chloroform.Pyridostigmine bromide is about one fifth as toxic asneostigmine. It appears to function in a manner similar tothat of neostigmine and is the most widely used anticholinesteraseagent for treating myasthenia gravis. Theliver enzymes and plasma cholinesterase metabolize thedrug. The principal metabolite is 3-hydroxy-N-methylpyridinium.Orally administered pyridostigmine has a half-lifeof 90 minutes and a duration of action of between 3 and6 hours.

상·하류 제품 정보

상류 원료

3-Pyridyl dimethylcarbamate3-피리딘올브롬화 메틸

공급사100 곳

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
Wuhan Chemwonders Technology Inc.027-85778276 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
重庆康洲智通医药科技有限公司173-08362167 17308362167 · [email protected]
Dayang Chem (Hangzhou) Co.,Ltd.+86-0571-88938639 17705817739 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
Syntechem Co.,Ltd[email protected]
上海迈瑞尔生化科技有限公司4006356688 18621169109 · [email protected]
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
安耐吉化学&3A(安徽泽升科技股份有限公司)400-0056266 · [email protected]
上海泰坦科技股份有限公司4006009262 13023226327 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
上海瀚香生物科技有限公司177-54423994 17754423994 · [email protected]
四川库利南科技有限公司400-1166-196 18981987031 · [email protected]
斯百全化学(上海)有限公司021-021-021-67601398-809-809-809 15221380277 · [email protected]
上海思域化工科技有限公司86-21-34053660 · [email protected]
TCI AMERICA800-4238616 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
深圳康特腾科技有限公司86-0755-86635001 · [email protected]
Hubei Datong Bio-Chemical Technology Co.,Ltd027-87666700 · [email protected]
广州爱纯医药科技有限公司020-39119399 18927568969 · [email protected]
湖北威德利化学试剂有限公司186-02735115 18602735115 · [email protected]
湖北鑫源顺医药化工有限公司13971561712, 13995564702, 027-50664929 · [email protected]
成都零六生物科技有限公司400-1166-196 13458535857 · [email protected]
南京恩德萨生物科技有限公司025-58862853 18915922038 · [email protected]
上海鑫圭生物科技有限公司15121041756 · [email protected]
江苏艾康生物医药研发有限公司025-66028182 17714375163 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
湖北巨胜科技有限公司027-59599241 18871490274 · [email protected]
池州凯隆进出口贸易有限公司[email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
桦特昇生物科技(武汉)有限公司027-59207879 1972026995 18140587686 · [email protected]
TargetMol中国(陶术生物)021-021-33632979 15002134094 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
斯派螺(武汉)药物研发有限公司[email protected]
九鼎化学(上海)科技有限公司4009209199 · [email protected]
湖北威德利化学科技有限公司027-83989310 18627915365 · [email protected]
湖北威德利化学试剂有限公司18327179646 · [email protected]
上海珞珐生化科技有限公司021-51111890 15317326293 · [email protected]
广州市齐云生物技术有限公司020-61288194 61288195 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
山东西亚化学有限公司4009903999 13395398332 · [email protected]
湖北威德利化学试剂有限公司13429867250 13429867250 · [email protected]
沧州恩科医药科技有限公司0317-5296180 15533709196 · [email protected]
成都华纯科技有限公司400-1166-196 15982826727 · [email protected]